Zhao Jidong, Zhang Xiangmei, He Ming, Chen Xin, Cui Xing, Qin Tian, Niu Xueliang, Zhao Liyan
Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
Onco Targets Ther. 2021 Feb 17;14:1113-1116. doi: 10.2147/OTT.S295813. eCollection 2021.
RAS mutations constitute one of the major tumorigenic mechanisms and are detected in approximately 20% of lung cancers. The most frequent mutated and well-studied RAS isoform is , which is associated with an overall poor prognosis in non-small-cell lung cancer (NSCLC). However, the clinical significances of and in NSCLC are rarely reported. Here, we present a 58-year-old male smoker who was diagnosed with stage IV lung adenosquamous carcinoma. A rare and double mutation was detected in the primary tumor and lymph node samples using next-generation sequencing (NGS). The patient showed rapid disease progression and passed away due to respiratory failure after 15 days of osimertinib in combination with cisplatin. To the best of our knowledge, this is the first report associating and double mutation in the poor prognosis of NSCLC.
RAS突变是主要的致瘤机制之一，在约20%的肺癌中可检测到。最常见的突变且研究充分的RAS亚型是 ，其与非小细胞肺癌（NSCLC）的总体预后不良相关。然而， 和 在NSCLC中的临床意义鲜有报道。在此，我们报告一名58岁男性吸烟者，他被诊断为IV期肺腺鳞癌。使用下一代测序（NGS）在原发肿瘤和淋巴结样本中检测到罕见的 和 双重突变。该患者疾病进展迅速，在奥希替尼联合顺铂治疗15天后因呼吸衰竭去世。据我们所知，这是首篇将 和 双重突变与NSCLC预后不良相关联的报告。
